All posts in
Better than ADCs? AstraZeneca bids for Bicyclic Peptides
Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer
7 European Institutions in the Largest Cancer Bioinformatics Collaboration
FDA and EMA review the First Therapy for a Deadly Skin Cancer
Drugging the Undruggable: New Acquisition to Boost GPCR Drugs
Sanofi quietly leaves Bladder Cancer Patients in the lurch
Celyad’s Autologous CAR-T Therapy enters Phase Ib
Can Oncolytic Viruses be the key to Treat Resistant Tumors?
Boehringer’s Biosimilar could take a Chunk out of the Cancer Market
Microbiomics recruited for Immuno-Oncology in a Huge New Partnership
Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed
How much of a Gamble is Investing in CRISPR?
Labiotech UG, All Rights Reserved -
Send this to friend